Skandinaviska Enskilda Banken (SEB)
IBRX icon

Skandinaviska Enskilda Banken (SEB)’s ImmunityBio IBRX Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,324,871
Closed -$2.62M – 422
2025
Q4 		$2.62M Hold
1,324,871
– – 0.01% 531
2025
Q3 		$3.25M Buy
1,324,871
+1,028,921
+348% +$2.65M 0.01% 492
2025
Q2 		$778K Hold
295,950
– – ﹤0.01% 670
2025
Q1 		$889K Hold
295,950
– – ﹤0.01% 653
2024
Q4 		$793K Buy
295,950
+25,000
+9% +$104K ﹤0.01% 680
2024
Q3 		$1.01M Hold
270,950
– – ﹤0.01% 668
2024
Q2 		$1.71M Hold
270,950
– – 0.01% 585
2024
Q1 		$1.46M Buy
+270,950
New +$1.23M 0.01% 621

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s IBRX Position: Q1 2026 in Review

Skandinaviska Enskilda Banken (SEB) sold out of ImmunityBio (IBRX) in Q1 2026, closing a stake of 1,324,871 shares — an estimated $2.62M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in IBRX in Q1 2024 and held it in 8 quarters. The position peaked at $3.25M in Q3 2025. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining ImmunityBio position as of Q1 2026 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 1,324,871 ImmunityBio shares in Q1 2026, an estimated $2.62M.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in ImmunityBio in Q1 2024 and held it in 8 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s ImmunityBio position peaked at $3.25M in Q3 2025.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2026, filed 15 May 2026.